FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
Eligibility criteria
Qualifiers
Biochemically diagnosed ACTH-dependent Cushing disease.
No previous pituitary surgery.
Planned to undergo pituitary surgery for localization/resection of adenoma.
No contraindications for PET/CT.
Disqualifiers
Pregnant as determined by a pregnancy test as per institutional guidelines for individuals of child-bearing potential
Declining to use effective contraceptive methods during the study (for individuals of child-bearing potential)
Need for emergent surgery that would be delayed by participation
Bacterial, viral, or fungal infections requiring systemic therapy
Trial design
Treatments tested in this trial
- Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov